ICARE AD-US is an observational real-world phase 4 study designed to evaluate the safety and effectiveness of ADUHELM in clinical practice ICARE AD-US is one of three programs to generate post-approval data on ADUHELM, including the re-dosing Phase 3b EMBARK study and the planned confirmatory Phase 4 post-marketing requirement study
Biogen aims to enroll at least 16 percent Latinx and Black/ African American patients with Alzheimer’s disease in the ICARE AD-US study as part of its commitment to increase participation from traditionally underrepresented communities
CAMBRIDGE, Mass. , July 29, 2021 (GLOBE NEWSWIRE) — Biogen (Nasdaq: BIIB) and Eisai Co., Ltd. ( Tokyo …
Read the source article at Stock Market Quotes and News
2021-07-29 21:10:11
